Affluent Medical : Affluent Medical announces the major success of its capital increase with preferential subscription rights for about €13.7 million
Sébastien Ladet, Chief Executive Officer of Affluent Medical, said: "I truly thank all the shareholders, and especially our reference shareholder Truffle Capital, who demonstrated their confidence with their participation to this capital increase that contributed to its great success.
- Sébastien Ladet, Chief Executive Officer of Affluent Medical, said: "I truly thank all the shareholders, and especially our reference shareholder Truffle Capital, who demonstrated their confidence with their participation to this capital increase that contributed to its great success.
- The gross amount of the Capital Increase is therefore €13,697,707.50 through the issue of 10,146,450 ABSARs at a unit subscription price of €1.35.
- The Company’s share capital after the capital increase will total €30,896,652 divided into 30,896,652 shares with a nominal value of €1 each.
- To the knowledge of the Company, the distribution of capital and voting rights following the Capital Increase is as follows: